Should I buy or sell Wave Life Sciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WVE shares. View WVE analyst ratings or view top-rated stocks .

What is Wave Life Sciences' stock price target for 2024?

7 analysts have issued 12 month price targets for Wave Life Sciences' stock. Their WVE share price targets range from $5.00 to $17.00. On average, they expect the company's share price to reach $10.14 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price. View analysts price targets for WVE or view top-rated stocks among Wall Street analysts .

How have WVE shares performed in 2024?

Wave Life Sciences' stock was trading at $5.05 at the beginning of 2024. Since then, WVE stock has decreased by 3.6% and is now trading at $4.87. View the best growth stocks for 2024 here .

When is Wave Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our WVE earnings forecast .

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) announced its earnings results on Wednesday, March, 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. The company earned $29.06 million during the quarter, compared to the consensus estimate of $23.30 million. During the same quarter in the previous year, the business posted ($0.47) earnings per share.

What ETFs hold Wave Life Sciences' stock?

ETFs with the largest weight of Wave Life Sciences (NASDAQ:WVE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com . Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD) , Exelixis (EXEL) , Sangamo Therapeutics (SGMO) , Sorrento Therapeutics (SRNE) , TherapeuticsMD (TXMD) , VBI Vaccines (VBIV) , Aduro Biotech (ADRO) , Cidara Therapeutics (CDTX) , CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN) .

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:WVE

Wave Life Sciences (WVE) Stock Price, News & Analysis

→ Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad)

Free WVE Stock Alerts

$4.87

+0.07 (+1.46%)

(As of 04/19/2024 ET)

Compare

Today's Range: $4.72
▼
$5.00
50-Day Range: $3.54
▼
$6.84
52-Week Range: $3.15
▼
$7.67

Volume: 452,641 shs
Average Volume: 861,126 shs
Market Capitalization: $595.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.14

Get Wave Life Sciences alerts:

Wave Life Sciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 108.3% Upside
$10.14 Price Target
Short Interest: Bearish
2.94% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.58
Upright™ Environmental Score
News Sentiment: 0.44
Based on 4 Articles This Week
Insider Trading: Selling Shares
$96,437 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.94) to ($1.07) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.11 out of 5 stars

Medical Sector

152nd out of 911 stocks

Pharmaceutical Preparations Industry

55th out of 411 stocks

3.4

Analyst's Opinion

Consensus Rating
Wave Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Wave Life Sciences has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.94% of the outstanding shares of Wave Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Wave Life Sciences has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Wave Life Sciences has recently increased by 19.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Wave Life Sciences does not currently pay a dividend.
Dividend Growth
Wave Life Sciences does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Wave Life Sciences has received a 77.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Wave Life Sciences is -0.58.

2.5

News and Social Media Coverage

News Sentiment
Wave Life Sciences has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Wave Life Sciences this week, compared to 2 articles on an average week.
MarketBeat Follows
5 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $96,437.00 in company stock.
Percentage Held by Insiders
31.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
89.73% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Wave Life Sciences are expected to decrease in the coming year, from ($0.94) to ($1.07) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Wave Life Sciences is -8.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Wave Life Sciences is -8.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Wave Life Sciences has a P/B Ratio of 12.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Timothy Sykes

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

About Wave Life Sciences Stock (NASDAQ:WVE)

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

WVE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

WVE Stock News Headlines

April 7, 2024 | insidertrades.com

Kyle Moran Sells 15,630 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock

April 16, 2024 | money.usnews.com

Wave Life Sciences Ltd.

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 13, 2024 | morningstar.com

WAVE Life Sciences Ltd

April 12, 2024 | americanbankingnews.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from Analysts

April 7, 2024 | investing.com

Wave Life Sciences CFO sells shares worth over $96k

April 4, 2024 | yahoo.com

100 Foot Wave Season 1 Streaming: Watch & Stream Online via HBO Max

April 1, 2024 | markets.businessinsider.com

Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 27, 2024 | globenewswire.com

Wave Life Sciences to Present at Upcoming Investor Conferences

March 23, 2024 | finance.yahoo.com

Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks

March 15, 2024 | msn.com

Wind and wave observations reveal the seasonal variations in wave-induced stress over global ocean

March 9, 2024 | finance.yahoo.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

March 8, 2024 | seekingalpha.com

Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche

March 8, 2024 | seekingalpha.com

Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2023 Earnings Call Transcript

March 6, 2024 | marketwatch.com

Wave Life Sciences Shares Rise 31% After Narrower-Than-Expected 4Q Loss

March 6, 2024 | msn.com

Wave Life Sciences GAAP EPS of -$0.15 beats by $0.08, revenue of $29.06M beats by $9.23M

March 6, 2024 | washingtonpost.com

Wave Life Sciences: Q4 Earnings Snapshot

March 6, 2024 | markets.businessinsider.com

Wave Life Sciences Gains 34% On Narrower Loss In Q4

March 6, 2024 | globenewswire.com

Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 5, 2024 | msn.com

Wave Life Sciences Q4 2023 Earnings Preview

March 2, 2024 | finance.yahoo.com

Wave Life Sciences Ltd. (WVE)

February 28, 2024 | globenewswire.com

Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024

February 27, 2024 | msn.com

Was the 100 Foot Wave Surfed? A Semi-Scientific Breakdown (Clip)

February 27, 2024 | globenewswire.com

Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy

February 24, 2024 | yahoo.com

10-Foot Wave Explodes on Surfer's Head, Friends Nearly Call 911 (Clip)

See More Headlines

Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:WVE
CUSIP: N/A
CIK: 1631574
Web: www.wavelifesciences.com
Phone: (656) 236-3388
Fax: 617-949-2901
Employees: 266
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.14
High Stock Price Target: $17.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +108.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.55)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-57,510,000.00
Net Margins: -50.76%
Pretax Margin: -51.36%
Return on Equity: N/A
Return on Assets: -23.67%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.26
Quick Ratio: 1.26

Sales & Book Value

Annual Sales: $113.31 million
Price / Sales: 5.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.40 per share
Price / Book: 12.18

Miscellaneous

Outstanding Shares: 122,280,000
Free Float: 84,254,000
Market Cap: $595.50 million
Optionable: Optionable
Beta: -1.12

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Paul B. Bolno M.B.A. (Age 50)
M.D., President, CEO & Director
Comp: $1.1M
Mr. Kyle B. Moran CFA (Age 53)
CFO & Principal Accounting Officer
Comp: $677.87k
Dr. Chandra Vargeese Ph.D. (Age 63)
Chief Technology Officer
Comp: $710.05k
Kate Rausch
Head of Investor Relations
Ms. Linda Rockett J.D.
Senior VP & General Counsel
Dr. Christopher Francis Ph.D. (Age 46)
Senior VP of Corporate Development & Head of Emerging Areas
Comp: $493.13k
Ms. Daryn Lewis
Senior VP & Head of Human Resources
Dr. Sridhar Vaddeboina Ph.D.
Senior Vice President of Chemistry, Manufacturing & Controls
Ms. Anne-Marie Li-Kwai-Cheung
Chief Development Officer
Dr. Hsiu-Chiung Yang Ph.D.
Senior Vice President of Translational Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

WVE Stock Analysis - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WVE shares.
View WVE analyst ratings or view top-rated stocks.
What is Wave Life Sciences' stock price target for 2024?: 7 analysts have issued 12 month price targets for Wave Life Sciences' stock. Their WVE share price targets range from $5.00 to $17.00. On average, they expect the company's share price to reach $10.14 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price.
View analysts price targets for WVE or view top-rated stocks among Wall Street analysts.
How have WVE shares performed in 2024?: Wave Life Sciences' stock was trading at $5.05 at the beginning of 2024. Since then, WVE stock has decreased by 3.6% and is now trading at $4.87.
View the best growth stocks for 2024 here.
When is Wave Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our WVE earnings forecast.
How were Wave Life Sciences' earnings last quarter?: Wave Life Sciences Ltd. (NASDAQ:WVE) announced its earnings results on Wednesday, March, 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.04. The company earned $29.06 million during the quarter, compared to the consensus estimate of $23.30 million. During the same quarter in the previous year, the business posted ($0.47) earnings per share.

What ETFs hold Wave Life Sciences' stock?: ETFs with the largest weight of Wave Life Sciences (NASDAQ:WVE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Nasdaq Future Gen 200 ETF (QQQS).
What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?: 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Wave Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).
How do I buy shares of Wave Life Sciences?: Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:WVE) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial